

The Effect of Low-Dose Esketamine on Postoperative Neurocognitive Dysfunction in Elderly Patients Undergoing General Anesthesia for Gastrointestinal Tumors: A Randomized Controlled Trial [Letter]

Yongjian Lin ^{1,*}, Mingyang Jiang ^{2,*}

¹Department of Gastrointestinal and Gland Surgery, the First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, People's Republic of China; ²Department of Orthopedics, the First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, People's Republic of China

*These authors contributed equally to this work

Correspondence: Mingyang Jiang, Email 202120576@sr.gxmu.edu.cn

Dear editor

We read with interest the study by Ma et al evaluated the effect of intraoperative application of low-dose esketamine on PND in elderly patients undergoing general anesthesia for gastrointestinal tumors.¹ This study demonstrated that low-dose esketamine infusion reduced the incidence of delayed neurocognitive recovery (DNR) to some extent, which improved intraoperative hemodynamics and alleviated postoperative pain. After reading this article carefully, we have some suggestions to point out as follows.

First, it is important to explore interactions in clinical studies, and we have no real understanding about the effects of various variables on PND in patients undergoing general anesthesia.² As the authors described the discussion, "Age, low education level, inflammation, postoperative pain, serum 25-OH-D level, and preoperative cognitive impairment as potential risk factors for postoperative cognitive dysfunction". Age, sex ratio, American Society of Anesthesiology (ASA) physical status I–III, body mass index (BMI), education level, preoperative complications (hypertension, diabetes, and coronary heart disease), and operative procedure were shown in Table 1. However, we did not find an interaction analysis based on these variables. Therefore, if subgroup analyses had been performed in this article based on these variables, the results might have been more enriched and novel.

Second, as statistical methods continue to improve, interpolation is a novel way of dealing with missing data.³ This method finds a reasonable alternative value for each missing data in a survey and then getting a complete data set to analyze and organize. As stated by the authors in the discussion, "six patients (8.8%) dropped out, two had incomplete information due to poor compliance, three withdrew from the trial, and one had a second operation within three days after surgery". However, the authors did not describe in detail the methodology for dealing with missing data. Next, intention-to-treat analysis would be the best option for clinical trials.⁴ Intention-to-treat analysis is based on the initial assignment of treatment, rather than the treatment ultimately received, and is designed to avoid a variety of misleading factors that could affect the results. It is our recommendation that interpolation be used to address missing data in clinical practice and that intention-to-treat analysis be applied to determine the reliability of the results.

Finally, the esketamine group (group Es) and the control group (group C) were well matched (Table 1), and their clinical characteristics did not differ significantly. In clinical studies, especially those conducted in multiple centers, it is almost impossible to balance the baseline characteristics of patients. Thus the results of this study may not truly reflect the conditions of patients in the real world. In addition, although the baseline characteristics of the two groups were comparable ($P > 0.05$), this paper still suggests multivariate logistic regression analysis for the comparison of adverse

clinical outcomes in both groups. In statistical modeling, regression analysis is a statistical process that estimates the relationship between variables.⁵ It includes many techniques for modeling and analyzing several variables. We sincerely recommend that the authors use multivariate logistic regression analysis to adjust for confounders and thus draw accurate conclusions that reflect the real world.

Disclosure

The authors report no conflicts of interest in this communication.

References

1. Jiamin M, Jiamin M, Jiamin M, Wang F, Wang F. The effect of low-dose esketamine on postoperative neurocognitive dysfunction in elderly patients undergoing general anesthesia for gastrointestinal tumors: a randomized controlled trial. *Drug Des Devel Ther.* 2023;17:1945–1957. doi:10.2147/DDDT.S406568
2. Overton RC. Moderated multiple regression for interactions involving categorical variables: a statistical control for heterogeneous variance across two groups. *Psychol Methods.* 2001;6(3):218–233. doi:10.1037/1082-989X.6.3.218
3. Gustafson SC, Parker DR, Martin RK. Cardinal interpolation. *IEEE Trans Pattern Anal Mach Intell.* 2007;29(9):1538–1545. doi:10.1109/TPAMI.2007.1170
4. Linfante I, Starosciak AK, Walker GR, Dabus G, Castonguay AC. Predictors of poor outcome despite recanalization: a multiple regression analysis of the NASA registry. *J Neurointerv Surg.* 2015;8(3):224–229. doi:10.1136/neurintsurg-2014-011525
5. Herman WH; The Diabetes Prevention Program Research Group. The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS (vol 35, 723, 2012). *Diabetes Care.* 2013;36:4173–4175.

Dove Medical Press encourages responsible, free and frank academic debate. The content of the Drug Design, Development and Therapy 'letters to the editor' section does not necessarily represent the views of Dove Medical Press, its officers, agents, employees, related entities or the Drug Design, Development and Therapy editors. While all reasonable steps have been taken to confirm the content of each letter, Dove Medical Press accepts no liability in respect of the content of any letter, nor is it responsible for the content and accuracy of any letter to the editor.

Drug Design, Development and Therapy

Dovepress

Publish your work in this journal

Drug Design, Development and Therapy is an international, peer-reviewed open-access journal that spans the spectrum of drug design and development through to clinical applications. Clinical outcomes, patient safety, and programs for the development and effective, safe, and sustained use of medicines are a feature of the journal, which has also been accepted for indexing on PubMed Central. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/drug-design-development-and-therapy-journal>

<https://doi.org/10.2147/DDDT.S430847>